Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,686,602
  • Shares Outstanding, K 54,974
  • Annual Sales, $ 607,520 K
  • Annual Income, $ 1,320 K
  • 60-Month Beta 0.90
  • Price/Sales 2.75
  • Price/Cash Flow 18.87
  • Price/Book 1.77
Trade SUPN with:

Options Overview Details

View History
  • Implied Volatility 77.23% ( +4.71%)
  • Historical Volatility 24.27%
  • IV Percentile 99%
  • IV Rank 93.24%
  • IV High 82.11% on 07/22/24
  • IV Low 9.83% on 08/18/23
  • Put/Call Vol Ratio 3.00
  • Today's Volume 4
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 2,457
  • Open Int (30-Day) 1,398

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.25
  • Number of Estimates 2
  • High Estimate 0.30
  • Low Estimate 0.21
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +1,350.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.55 +20.35%
on 07/03/24
31.44 -2.19%
on 07/26/24
+4.03 (+15.08%)
since 06/26/24
3-Month
25.53 +20.45%
on 06/14/24
32.87 -6.45%
on 05/09/24
+0.68 (+2.26%)
since 04/26/24
52-Week
21.99 +39.84%
on 10/27/23
35.44 -13.23%
on 03/21/24
+0.56 (+1.85%)
since 07/26/23

Most Recent Stories

More News
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 30.75 (+0.23%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 30.75 (+0.23%)
Supernus: Q2 Earnings Snapshot

Supernus: Q2 Earnings Snapshot

SUPN : 30.75 (+0.23%)
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy

Supernus Pharmaceuticals' revenue mix is shifting, and it could soon have more sales on the way.

SUPN : 30.75 (+0.23%)
Supernus: Q1 Earnings Snapshot

Supernus: Q1 Earnings Snapshot

SUPN : 30.75 (+0.23%)
Supernus: Q4 Earnings Snapshot

Supernus: Q4 Earnings Snapshot

SUPN : 30.75 (+0.23%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 30.75 (+0.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 30.75 (+0.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. (""Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 30.75 (+0.23%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN)....

SUPN : 30.75 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 32.49
2nd Resistance Point 31.96
1st Resistance Point 31.36
Last Price 30.75
1st Support Level 30.23
2nd Support Level 29.70
3rd Support Level 29.10

See More

52-Week High 35.44
Last Price 30.75
Fibonacci 61.8% 30.30
Fibonacci 50% 28.72
Fibonacci 38.2% 27.13
52-Week Low 21.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar